DR
DRUG.US Bright Minds Biosciences Inc
- Market cap
- USD 228M
- P/E
- -
- P/B
- 1.03x
- ROE
- -8.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is DRUG.US undervalued?
Graham numberThe Graham number of Bright Minds Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bright Minds Biosciences Inc fundamental analysis
No fundamental analysis for Bright Minds Biosciences Inc yet.
Bright Minds Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. Th…
Full company profileBright Minds Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bright Minds Biosciences Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | -6.04K | -72.5K | - | -77.0K | -79.8K |
| Operating Income | -236K | -469K | -8.76M | -15.0M | -7.39M | -2.82M | -13.9M | -45.6M |
| EBITDA | -78.7K | -469K | -8.76M | -15.0M | -7.30M | -2.73M | -12.2M | -39.8M |
| Net Income | -236K | -486K | -8.52M | -15.0M | -7.37M | -2.80M | -12.2M | -27.5M |
| EPS | -0.18 | -0.38 | -4.74 | -6.06 | -1.98 | -0.65 | -1.78 | -2.80 |
| Balance Sheet | ||||||||
| Total Assets | 164K | 880K | 20.0M | 12.1M | 6.88M | 6.10M | 84.4M | 311M |
| Total Liabilities | 36.7K | 151K | 639K | 1.54M | 281K | 568K | 2.38M | 2.55M |
| Shareholders' Equity | 127K | 729K | 19.4M | 10.5M | 6.60M | 5.54M | 82.0M | 308M |
| Cash & Short-term Investments | 80.0K | 800K | 19.8M | 11.6M | 6.75M | 5.72M | 82.9M | 308M |
| Total Debt | - | - | - | 140K | 73.5K | 119K | 126K | 65.7K |
| Cash Flow | ||||||||
| Operating Cash Flow | -42.0K | -288K | -7.32M | -13.6M | -7.02M | -1.85M | -8.69M | -31.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 5.00 | 0.00 | 0.00 | 5.57 |
| Free Cash Flow | -42.0K | -288K | -7.32M | -13.6M | -7.02M | -1.85M | -8.69M | -31.6M |
| Ratios | ||||||||
| ROE | -185.6% | -66.6% | -43.9% | -141.9% | -111.7% | -50.6% | -14.9% | -8.9% |
| ROA | -144.0% | -55.2% | -42.5% | -123.8% | -107.2% | -45.9% | -14.5% | -8.9% |
| Debt to Equity | - | - | - | 0.01x | 0.01x | 0.02x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bright Minds Biosciences Inc dividends
Bright Minds Biosciences Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:5 on Jul 14, 2023.
Who owns Bright Minds Biosciences Inc
- Insiders 11.56%
- Institutions 88.44%
- Public & others 0.00%
- Shares outstanding 9.86M
- Free float 6.74M
Top funds holding DRUG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 179K | 1.81% | 0.00% | Oct 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 166K | 1.68% | 0.00% | Jun 2026 |
| Eventide Healthcare & Life Sciences I | 130K | 1.32% | 0.00% | Jun 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 104K | 1.05% | 0.00% | Sep 2026 |
| BlackRock Health Sciences Opps Inv A | 95.7K | 0.97% | 0.00% | Sep 2026 |
| Biotech Growth Ord | 93.0K | 0.94% | 0.00% | Jul 2026 |
| Fidelity Small Cap Index | 81.2K | 0.82% | 0.00% | Aug 2026 |
| BGF World Healthscience A2 | 75.1K | 0.76% | 0.00% | Jul 2026 |
| iShares Russell 2000 Growth ETF | 66.8K | 0.68% | -0.38% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 55.4K | 0.56% | +0.27% | Oct 2026 |
| Driehaus Micro Cap Growth USD | 41.6K | 0.42% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 41.1K | 0.42% | -3.38% | Sep 2026 |
| AdvisorShares Psychedelics ETF | 38.2K | 0.39% | 0.00% | Oct 2026 |
| BlackRock Health Sciences Term Trust | 31.9K | 0.32% | 0.00% | Jun 2026 |
| iShares Micro-Cap ETF | 21.5K | 0.22% | 0.00% | Oct 2026 |
| Adara Smaller Companies | 20.1K | 0.20% | -0.56% | Sep 2026 |
| GS US Sm Cp CORE Eq Base Inc USD Snap | 20.0K | 0.20% | +1.10% | Aug 2026 |
| Goldman Sachs Small Cap Eq Insghts Instl | 18.8K | 0.19% | +327.81% | Jul 2026 |
| Schwab Small Cap Index | 17.2K | 0.17% | -4.67% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 12.8K | 0.13% | -7.77% | Sep 2026 |
Top institutions holding DRUG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 1.35M | 13.68% | 0.00% | Jun 2026 |
| Cormorant Asset Management, LLC | 900K | 9.12% | -15.04% | Jun 2026 |
| BlackRock Inc | 686K | 6.96% | +10.33% | Jun 2026 |
| Vivo Capital, LLC | 557K | 5.65% | 0.00% | Jun 2026 |
| Vestal Point Capital LP | 545K | 5.53% | +10.70% | Jun 2026 |
| BRAIDWELL LP | 484K | 4.90% | -10.35% | Jun 2026 |
| Driehaus Capital Management LLC | 433K | 4.39% | +0.20% | Jun 2026 |
| Balyasny Asset Management LLC | 345K | 3.50% | +16.12% | Jun 2026 |
| Adage Capital Partners Gp LLC | 335K | 3.40% | -32.42% | Jun 2026 |
| Point72 Asset Management, L.P. | 327K | 3.32% | 0.00% | Jun 2026 |
| Deerfield Management Co | 283K | 2.87% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 265K | 2.69% | 0.00% | Jun 2026 |
| Parkman Healthcare Partners LLC | 205K | 2.08% | +411.38% | Jun 2026 |
| MPM Oncology Impact Management LP | 202K | 2.05% | -4.74% | Jun 2026 |
| Wellington Management Company LLP | 171K | 1.74% | +25.34% | Jun 2026 |
| The Goldman Sachs Group Inc | 134K | 1.36% | +79.76% | Jun 2026 |
| Eventide Asset Management, LLC | 130K | 1.32% | 0.00% | Jun 2026 |
| State Street Corp | 122K | 1.24% | +12.88% | Jun 2026 |
| SEVEN GRAND MANAGERS, LLC | 120K | 1.22% | 0.00% | Jun 2026 |
| Great Point Partners LLC | 110K | 1.11% | -50.18% | Jun 2026 |
Bright Minds Biosciences Inc company profile
- Company name
- Bright Minds Biosciences Inc
- Ticker
- DRUG.US
- ISIN
- CA10919W4056
- Exchange
- USA Stocks
- Listed since
- Mar 22, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 26
- Fiscal year end
- September
- Address
- 19 Vestry Street, New York, NY, United States, 10013
- Phone
- 647 865 8622
- Website
- brightmindsbio.com
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Bright Minds Biosciences Inc management
6- Mr. Ian McDonaldCo-Founder, CEO, President & Director · born 1988
- Mr. Ryan E. S. K. Cheung B.Com., C.A., CPACFO & Corporate Secretary · born 1978
- Dr. Jan Torleif Pedersen M.Sc., Ph.D.Chief Science Officer & Director · born 1965
- Mr. Alex VasilkevichCOO & Senior Scientific Officer · born 1989
- Dr. Emer Leahy M.B.A., Ph.D.Consultant · born 1967
- Dr. Stephen D. Collins M.D., Ph.D.Chief Medical Officer · born 1953